Lara-Ávila L, Herrera-Salazar A, Morgan-Ortiz F, Medina-Bastidas D, Arámbula-Meráz E, Osuna-Ramírez I

Language: Spanish
References: 24
Page: 354-360
PDF size: 309.78 Kb.

ABSTRACT

Background: Recently, the angiogenic activity of chymase and its ability to promote similar to the vascular endothelial growth factor vascular proliferation was demonstrated. During pregnancy, it has been reported elevated enzyme activity of chymase in serum of women with and without preeclampsia.
Objetive: To evaluate whether there are differences in serum chymase among women with preeclampsia and healthy pregnant women and its usefulness as a biochemical marker of disease.
Material and Methods: It was conducted study of cases and controls, in which the concentration of chymase was analyzed with ELISA in maternal serum of 15 patients with preeclampsia (cases) and 15 healthy pregnant women (controls) matched for gestational age, maternal age and number of pregnancies. Serum chymase in patients with preeclampsia according to the presence or absence of severity criteria was compared.
Results: The mean in the case group was 4.38 ng / dl and 1.2 ng / dl in the control group (p = 0.006) were statistically significant differences between groups. When making a comparison between the case group according to the presence of criteria of severity of preeclampsia were no significant differences between groups with an average serum level of 5.5 ng (SD: 4.7) were found in the group without criteria of severity and of 3.6ng (SD: 2.9) in patients with severity criteria (p=.342).
Conclusions: Serum levels of chymase are significantly higher in patients with preeclampsia than in patients with pregnancies without hypertension.

REFERENCES

1. Ilekis JV, Tsilou E, Fisher S, Abrahams VM, Soares MJ, Cross JC, et al. Placental origins of adverse pregnancy outcomes: potential molecular targets: an Executive Workshop Summary of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Am J Obstet Gynecol 2016; doi: 10.1016/j.ajog.2016.03.001. [Epub ahead of print]

2. Andraweera PH, Dekker GA, Roberts CT. The vascular endothelial growth factor family in adverse pregnancy outcomes. Hum Reprod Update 2012;18(4):436-57.

3. Wang Y, Gu Y, Lewis DF, Alexander JS, Granger DN. Elevated plasma chymotrypsin-like protease (Chymase) activity in women with preeclampsia. Hypertens Pregnancy 2010;29(3):253-261.

4. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990;265(36):22348-22357.

5. Wang Y, Alexander JS. Role of chymase in preeclampsia. Curr Vasc Pharmacol 2013;11(5):606-15.

6. Wang Y, Gu Y, Lewis D. Endothelial angiotensin II generation induced by placenta-derived factors from preeclampsia. Reprod Sci 2008;15(9):932-938.

7. Mitani R, Maeda K, Fukui R, Endo S, Saijo Y, Shinohara K, Kamada M, Irahara M, Yamano S, Nakaya Y, Aono T. Production of human mast cell chymase in human myometrium and placenta in cases of normal pregnancy and preeclampsia. Eur J Obstet Gynecol Reprod Biol 2002;101(2):155-60.

8. Nielsen AH, Schauser KH, Poulsen K. Current topic: the uteroplacental renin-angiotensin system. Placenta 2000;21(5- 6):468-77.

9. Broughton Pipkin F, Craven DJ, Symonds EM. The uteroplacental renin-angiotensin system in normal and hypertensive pregnancy. Contrib Nephrol 1981;25:49-52.

10. Taira H, Mizutani S, Narita O, Tomoda Y. Angiotensin I-converting enzyme in human placenta. Placenta 1985;6(6):543-9.

11. Walsh SW. Preeclampsia: an imbalance in placental prostacyclin and thromboxane production. Am J Obstet Gynecol 1985;152(3):335-40.

12. Nelson DM, Walsh SW. Thromboxane and prostacyclin production by different compartments of the placental villus. J Clin Endocrinol Metab 1989;68(3):676-83.

13. Walsh SW, Wang Y. Trophoblast and placental villous core production of lipid peroxides, thromboxane, and prostacyclin in preeclampsia. J Clin Endocrinol Metab 1995;80(6):1888-93.

14. Levin ER. Endothelins. N Engl J Med 1995; 333:356-63.

15. Le SQ, Wasserstrum N, Mombouli JV, Vanhoutte PM. Contractile effect of endothelin in human placental veins: role of endothelium prostaglandins and thromboxane. Am J Obstet Gynecol 1993;169(4):919-24.

16. Benoit C, Zavecz J, Wang Y. Vasoreactivity of chorionic plate arteries in response to vasoconstrictors produced by preeclamptic placentas. Placenta 2007;28(5-6):498- 504.

17. Urata H, Kinoshita A, Perez DM, Misono KS, Bumpus FM, Graham RM, et al. Cloning of the gene and cDNA for human heart chymase. J Biol Chem 1991;266(26):17173-9.

18. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993;91(4):1269-81.

19. Wang Y, Gu Y, Zhang Y, Lewis DF, Alexander JS, Granger DN. Increased chymotrypsin-like protease (chymase) expression and activity in placentas from women with preeclampsia. Placenta 2007;28(4):26-9.

20. Gu Y, Liu C, Alexander JS, Groome LJ, Yuping Wang. Chymotrypsin- Like Protease (Chymase) mediates endothelial activation by factors derived from preeclamptic placentas. Reprod Sci 2009;16(9):905-913.

21. Gu Y, Groome LJ, Alexander JS, Wang Y. PAR-2 triggers placenta-derived protease-induced altered VE-cadherine reorganization at endothelial junctions in preeclampsia. Placenta 2012;33(10):803-809.

22. Zhao S, Gu Y, Fan R, Groome LJ, Cooper D, Wang Y. Proteases and sFlt-1 release in the human placenta. Placenta 2010;31(6):512-518.

23. Nakano A, Kishi F, Minami K, Wakabayashi H, Nakaya Y, Kido H. Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells. J Immunol. 1997; 159(4):1987-1992.

24. Leik CE, Walsh SW. Neutrophils infiltrate resistance-sized vessels of subcutaneous fat in women with preeclampsia. Hypertension. 2004;44(1):72-77.